Table 3.
Validity of genotypes in predicting efavirenz plasma concentrations above 4 μg/mL.
| Risk factors for EFV plasma concentration > 4 μg/mL | Sensitivity (%) | Specificity (%) | Positive predictive value (%) | Negative predictive value (%) |
|---|---|---|---|---|
| CYP2B6 c.516T/T | 47.8 | 93.5 | 76.7 | 79.9 |
| CYP2B6 c.983C/C | 7.2 | 100 | 100 | 70.0 |
| CYP2B6 c.485-18C/C | 97.1 | 14.7 | 35.1 | 91.3 |
| CYP2B6 c.1421T/T | 83.1 | 44.4 | 40.6 | 85.1 |
| NR1I3 c.239-1089C/C | 42.0 | 67.8 | 37.2 | 72.0 |
| ABCB1 c.193G/G | 4.3 | 97.4 | 42.9 | 69.3 |
| CYP2B6 poor metabolizers (i.e., c.516T/T or c.983C/C or c.516G/T + c.983T/C) | 68.1 | 93.4 | 82.5 | 86.5 |
| CYP2B6 poor metabolizers together with CYP2B6 c.485-18C carriers | 69.1 | 93.0 | 82.5 | 86.3 |
| CYP2B6 poor metabolizers together with CYP2B6 c.1421T carriers | 66.2 | 94.4 | 84.3 | 85.9 |
| CYP2B6 poor metabolizers together with NR1I3 c.239-1089C carriers | 58.0 | 97.3 | 90.9 | 83.2 |
| CYP2B6 poor metabolizers together with ABCB1 c.193G carriers | 17.4 | 97.4 | 75.0 | 72.1 |